Soleno Therapeutics (SLNO) Competitors $86.21 +3.58 (+4.33%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$86.61 +0.40 (+0.47%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. SNN, SOLV, PEN, STVN, GKOS, IRTC, NARI, TMDX, BLCO, and INSPShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), TransMedics Group (TMDX), Bausch + Lomb (BLCO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Inari Medical TransMedics Group Bausch + Lomb Inspire Medical Systems Smith & Nephew SNATS (NYSE:SNN) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do insiders and institutionals believe in SNN or SLNO? 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, SNN or SLNO? Smith & Nephew SNATS has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.63, indicating that its stock price is 363% less volatile than the S&P 500. Which has preferable earnings & valuation, SNN or SLNO? Smith & Nephew SNATS has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew SNATS$5.81B2.27$412M$2.1613.96Soleno TherapeuticsN/AN/A-$175.85M-$4.62-18.66 Is SNN or SLNO more profitable? Smith & Nephew SNATS's return on equity of 0.00% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Smith & Nephew SNATSN/A N/A N/A Soleno Therapeutics N/A -77.52%-63.44% Does the media favor SNN or SLNO? In the previous week, Soleno Therapeutics had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 5 mentions for Soleno Therapeutics and 1 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.22 beat Soleno Therapeutics' score of 0.77 indicating that Smith & Nephew SNATS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SNN or SLNO? Smith & Nephew SNATS currently has a consensus target price of $28.00, indicating a potential downside of 7.16%. Soleno Therapeutics has a consensus target price of $107.10, indicating a potential upside of 24.23%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummarySmith & Nephew SNATS beats Soleno Therapeutics on 8 of the 15 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.16B$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-18.668.8326.2319.90Price / SalesN/A663.86413.23113.66Price / CashN/A151.5836.1356.90Price / Book15.184.548.045.38Net Income-$175.85M$31.16M$3.15B$248.50M7 Day Performance2.61%-0.40%1.44%2.04%1 Month Performance11.40%6.76%3.62%4.84%1 Year Performance105.12%1.17%34.68%20.23% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.2194 of 5 stars$86.21+4.3%$107.10+24.2%+117.0%$4.16BN/A-18.6630SNNSmith & Nephew SNATS3.7704 of 5 stars$29.17+1.2%$28.00-4.0%+22.2%$12.77B$5.81B13.5017,349SOLVSolventum0.893 of 5 stars$73.21-0.5%$80.29+9.7%+51.6%$12.67B$8.31B33.8922,000Positive NewsAnalyst UpgradePENPenumbra4.7337 of 5 stars$254.41-1.0%$302.40+18.9%+41.8%$9.85B$1.19B240.014,500Positive NewsSTVNStevanato Group0.9691 of 5 stars€23.62+1.4%N/A+36.2%€7.15B€1.19B46.315,521Analyst ForecastGKOSGlaukos4.3459 of 5 stars$96.80-3.3%$134.67+39.1%-12.8%$5.53B$383.48M-40.84780IRTCiRhythm Technologies1.2379 of 5 stars$150.95+3.6%$138.60-8.2%+44.8%$4.82B$591.84M-48.072,000Positive NewsInsider TradeNARIInari Medical0.4688 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800TMDXTransMedics Group1.6004 of 5 stars$127.53+3.2%$127.33-0.2%-14.3%$4.31B$441.54M93.77210Positive NewsBLCOBausch + Lomb3.3738 of 5 stars$12.01+2.3%$15.54+29.5%-6.2%$4.25B$4.79B-11.6613,500INSPInspire Medical Systems4.8514 of 5 stars$129.88-0.8%$211.91+63.2%-2.7%$3.83B$840.11M59.851,246Positive News Related Companies and Tools Related Companies Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives iRhythm Technologies Alternatives Inari Medical Alternatives TransMedics Group Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
